Clinical Trials at USC

1482 Results for

Study Title	Principal Investigator
A Phase Ib Ascending Multi-arm, Dose Escalation Study of BMS-906024 Combined With Several Chemotherapy Regimens in Subjects With Advanced or Metastatic Tumors DLTs = dose-limiting toxicities MTD = Maximum tolerated dose Not recruiting \| Any Cancer Condition or Solid Tumor \| Multisite View full trial information >>	Bristol-Myers Squibb
A Phase II Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma This Phase II study will enroll patients into three groups. Group 1 are patients who have never been treated with bevacizumab. These patients will be randomly assigned to receive either rindopepimut/GM-CSF or KLH, each along with bevacizumab. Treatment assignment for Group 1 will be blinded. Group 2 and Group 2C patients are those who are refractory to bevacizumab (experienced recurrence or progression of glioblastoma while on bevacizumab or within 2 months of discontinuing bevacizumab). These patients will all receive rindopepimut/GM-CSF along with bevacizumab. Patients will be treated until disease progression or intolerance and all patients will be followed for survival. Patients may be treated with other therapies that are not part of the study after discontinuing treatment with the study vaccine. Not recruiting \| Brain Cancer \| Multisite View full trial information >>	Naveed Wagle View Research Profile
<< < 60 61 62 63 64 ... 66 >>